Aik-Choon Tan

Ensemble machine learning on gene expression data for cancer classification.

MSAT: a multiple sequence alignment tool based on TOPS.

Multi-class protein fold classification using a new ensemble machine learning approach.

Simple decision rules for classifying human cancers from gene expression profiles.

Robust prostate cancer marker genes emerge from direct integration of inter-study microarray data.

Allele-specific expression in the germline of patients with familial pancreatic cancer: an unbiased approach to cancer gene discovery.

Merging microarray data from separate breast cancer studies provides a robust prognostic test.

Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer.

Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer.

Identification of novel serological biomarkers for inflammatory bowel disease using Escherichia coli proteome chip.

Characterizing DNA methylation patterns in pancreatic cancer genome.

Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer.

Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts.

A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells.

Novel agents in the treatment of metastatic colorectal cancer.

Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development.

Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer.

Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.

The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models.

Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.

A survey of statistical software for analysing RNA-seq data.

Quantitative proteomic analysis of ovarian cancer cells identified mitochondrial proteins associated with Paclitaxel resistance.

Confident predictability: identifying reliable gene expression patterns for individualized tumor classification using a local minimax kernel algorithm.

A short survey of computational analysis methods in analysing ChIP-seq data.

MIR29B regulates expression of MLLT11 (AF1Q), an MLL fusion partner, and low MIR29B expression associates with adverse cytogenetics and poor overall survival in AML.

A DNA methylation fingerprint of 1628 human samples.

Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy.

Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.

Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2.

Host response transcriptional profiling reveals extracellular components and ABC (ATP-binding cassette) transporters gene enrichment in typhoid fever-infected Nigerian children.

Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch.

Direct reprogramming of human fibroblasts into dopaminergic neuron-like cells.

Employing gene set top scoring pairs to identify deregulated pathway-signatures in dilated cardiomyopathy from integrated microarray gene expression data.

BiNGS!SL-seq: a bioinformatics pipeline for the analysis and interpretation of deep sequencing genome-wide synthetic lethal screen.

Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.

Patient-derived tumour xenografts as models for oncology drug development.

ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ-secretase inhibitor and irinotecan in colorectal cancer.

Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib.

ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53.

Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition.

Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models.

Obesity and overfeeding affecting both tumor and systemic metabolism activates the progesterone receptor to contribute to postmenopausal breast cancer.

Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer.

A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and neck squamous carcinoma cell lines.

Genomic signatures of pregnancy-associated breast cancer epithelia and stroma and their regulation by estrogens and progesterone.

Tumor P-Glycoprotein Correlates with Efficacy of PF-3758309 in in vitro and in vivo Models of Colorectal Cancer.

Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models.

MERTK receptor tyrosine kinase is a therapeutic target in melanoma.

A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins.

A genetic screen identifies TCF3/E2A and TRIAP1 as pathway-specific regulators of the cellular response to p53 activation.

Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer.

Collagen architecture in pregnancy-induced protection from breast cancer.

Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia.

The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.

Plasma-based circulating MicroRNA biomarkers for Parkinson's disease.

Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.

From bench to bedside: lessons learned in translating preclinical studies in cancer drug development.

K-Map: connecting kinases with therapeutics for drug repurposing and development.

BEReX: Biomedical Entity-Relationship eXplorer.

DNA methylation profiling revealed promoter hypermethylation-induced silencing of p16, DDAH2 and DUSP1 in primary oral squamous cell carcinoma.

Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer.

Automatic context-specific subnetwork discovery from large interaction networks.

Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer.

FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.

Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy.

Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.

Homeoprotein Six2 promotes breast cancer metastasis via transcriptional and epigenetic control of E-cadherin expression.

Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants.

Long term storage of dry versus frozen RNA for next generation molecular studies.

Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer.

Contrasting roles for C/EBPα and Notch in irradiation-induced multipotent hematopoietic progenitor cell defects.

TWIST1-Induced miR-424 Reversibly Drives Mesenchymal Programming while Inhibiting Tumor Initiation.

Systems biology approaches for advancing the discovery of effective drug combinations.

p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer.

RIP1 negatively regulates basal autophagic flux through TFEB to control sensitivity to apoptosis.

An Inducible TGF-β2-TGFβR Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases.

DSigDB: drug signatures database for gene set analysis.

FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers.

Comparative Haploid Genetic Screens Reveal Divergent Pathways in the Biogenesis and Trafficking of Glycophosphatidylinositol-Anchored Proteins.

Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models.

iCOSSY: An Online Tool for Context-Specific Subnetwork Discovery from Gene Expression Data.

A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer.

Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition data.

Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.

Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.

Aging-associated inflammation promotes selection for adaptive oncogenic events in B cell progenitors.

Expanding the computational toolbox for interrogating cancer kinomes.

An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer.

The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p.

A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma.

PKCδ regulates integrin αVβ3 expression and transformed growth of K-ras dependent lung cancer cells.

IMPACT: a whole-exome sequencing analysis pipeline for integrating molecular profiles with actionable therapeutics in clinical samples.

Genetically-defined novel oral squamous cell carcinoma cell lines for the development of molecular therapies.

BRONCO: Biomedical entity Relation ONcology COrpus for extracting gene-variant-disease-drug relations.

The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.

Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies.

Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.

Exploiting receptor tyrosine kinase co-activation for cancer therapy.

HiPub: translating PubMed and PMC texts to networks for knowledge discovery.

Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.

Systematic analysis of tumour cell-extracellular matrix adhesion identifies independent prognostic factors in breast cancer.

Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation.

Big Data Mining and Adverse Event Pattern Analysis in Clinical Drug Trials.

Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2.

AZ1366: An inhibitor of tankyrase and the canonical Wnt pathway that limits the persistence of non-small cell lung cancer cells following EGFR inhibition.